

Sterling Biotech Limited  
Registered Office : 43, Atlanta Building, Nariman Point, Mumbai - 400021.

AUDITED FINANCIAL RESULTS  
FOR THE YEAR ENDED 31st DECEMBER, 2007

(Rs. In Lakhs)

Sr. No.	Particulars	9 months ended (30/09/2007)	Quarter ended (31/12/2007)	Corresponding Quarter ended (31/12/2006)	Twelve Months ended (31/12/2007)	For the year ended (31/12/2006)
		Unaudited	Unaudited	Unaudited	Audited	Audited
1	Net Sales/Income from Operations	64,955.24	26,129.52	16,829.43	91,084.76	60,585.36
2	Other Income	732.87	262.97	216.73	995.84	504.52
3	<b>Total Income (1+2)</b>	65,688.11	26,392.49	17,046.16	92,080.60	61,089.88
4	Expenditure					
	a Increase/decrease in stock in trade and work in progress	(6,164.21)	417.92	(423.69)	(5,746.29)	(1,268.81)
	b Consumption of raw materials	28,402.98	8,949.63	5,826.20	37,352.61	20,997.60
	c Employees Cost	1,500.64	936.78	440.80	2,437.42	1,626.88
	d Depreciation	6,474.67	2,151.30	1,778.61	8,625.97	6,202.55
	e Other expenditure	11,534.19	4,641.62	3,078.38	16,175.81	10,509.47
	f Total	41,748.27	17,097.25	10,700.30	58,845.52	38,067.69
5	Interest	3,037.88	1,097.32	1,028.07	4,135.20	4,116.70
6	<b>Profit(+)/Loss (-) from Ordinary Activities before tax (3) - (4+5+6)</b>	20,901.96	8,197.92	5,317.79	29,099.88	18,905.49
7	Tax expense					
	a) Current	2,215.00	935.00	550.00	3,150.00	1,900.00
	b) Deffered	4,250.00	2,100.00	850.00	6,350.00	2,850.00
	c) Fringe Benefit	17.99	22.01	4.69	40.00	30.75
	d) Total	6,482.99	3,057.01	1,404.69	9,540.00	4,780.75
8	<b>Net Profit (+)/Loss (-) from Ordinary Activities after tax (7- 8)</b>	14,418.97	5,140.91	3,913.10	19,559.88	14,124.74
9	Extraordinary Items	801.51	209.25	161.27	1,010.76	645.14
10	<b>Net Profit (+)/Loss (-) for the period (9-10)</b>	13,617.46	4,931.66	3,751.83	18,549.12	13,479.60
11	Prior Year Adjustment	0.00	0.00	0.00	178.59	128.99
12	<b>Profit available for appropriation</b>	13,617.46	4,931.66	3,751.83	18,370.53	13,350.61
13	Paid-up equity share capital (Face Value of Rs.1/- per share)	2,289.02	2,294.76	2,223.48	2,294.76	2,223.48
14	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year.				126,895.57	99,048.80
15	Earnings Per Share (EPS)					
	a) Basic and diluted EPS before Extraordinary itmes for the period, for the year to date and for the previous year (not to be annualized)	6.30	2.24	1.76	8.52	6.35
	b) Basic and diluted EPS after Extraordinary itmes for the period, for the year to date and for the previous year (not to be annualized)	5.95	2.15	1.69	8.08	6.06
16	Public Shareholding					
	- Number of shares	150,929,206	151,502,854	152,125,969	151,502,854	152,125,969
	- Percentage of shareholding	65.94%	66.02%	68.42%	66.02%	68.42%

Notes:

- 1 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- 2 The above Audited financial results were reviewed by the audit committee and approved by the Board of Directors at its meeting held on 31st March, 2008.
- 3 The Board has recommended 50% Dividend (Rs.0.50 per equity share of Rs.1/- each) subject to approval of members at the ensuing Annual General Meeting.
- 4 During the quarter the Company has issued 573,648 equity shares of Rs.1/- each pursuant to conversion of FCCBs.
- 5 The number of investor complaints for the quarter ended on 31st December, 2007 were :  
Opening - 3, Received - 14, Disposed off - 14, and Balance - 3.

For and on Behalf of  
**STERLING BIOTECH LIMITED**

Place : Mumbai  
Date : 31st March, 2008

**Nitin J. Sandesara**  
**Chairman & Managing Director**